Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Appointment of US-based Chief Medical Officer

Posted on: 11 Apr 18

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that Dr Richard Beckman has joined the Company as Chief Medical Officer.  He replaces Dr Julian Howell who has left the Company to pursue another opportunity.


Dr Beckman brings to ReNeuron more than 25 years of executive and consultancy experience in drug and device development.  Prior to joining ReNeuron, Dr Beckman was the Chief Medical Officer of several innovative biotech and device firms, including Clearside, Ophthotech and Neurotech.  Prior to that, he had leadership roles at Alcon, Lux Bio, Becton Dickinson and Allergan.


Dr Beckman received his MD from the University of Michigan, completed a residency in ophthalmology at Henry Ford Hospital, and a glaucoma fellowship at the Mass. Eye and Ear Infirmary/Harvard University.   Prior to joining industry, he practised in academic medicine for three years at Cornell University Medical College and was in private practice for 10 years.


Dr Beckman will be based in ReNeuron’s recently established US office in Boston, MA, where he will lead the Company’s clinical and medical affairs team.


Commenting on Dr Beckman’s appointment, Olav Hellebø, Chief Executive Officer of ReNeuron, said:


“I am delighted to welcome Rick to the Company’s management team.  His many years’ experience in medical practice and industry in the US will be invaluable to us as we build out our Boston team and increase our clinical activities in the US.  I would like to express my sincere thanks on behalf of the Company to Julian Howell who has led our clinical and medical team so skilfully.  We wish him well in his next endeavour.”


Commenting on his appointment, Dr Beckman said:


“I am excited to be joining the experienced and talented team at ReNeuron.  I am grateful for the opportunity to help facilitate the translation of the Company’s transformative technology to previously untreatable diseases in neurology and ophthalmology.”

Editor's Details

Mike Wood

Last updated on: 11/04/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.